As of Q4'25, Johnson & Johnson reported R&D Expenses of USD 4.25B and SG&A Expenses of USD 6.95B. This marks a notable increase in both categories compared to the previous quarter, with SG&A Expenses reaching their highest level in the period covered. From Q1'23 to Q4'25, the chart shows that both R&D and SG&A Expenses have experienced fluctuations, but the overall trend is upward, especially in SG&A Expenses, which saw a significant dip in Q4'23 before rebounding strongly. R&D Expenses also peaked in Q4'24 at USD 5.3B before moderating, while SG&A Expenses demonstrated more volatility but ended the period at a new high, indicating increased investment in both research and administrative functions toward the end of the observed timeframe.